Home › Neuroblastoma › Iowa › Cedar Rapids
Neuroblastoma clinical trials in Cedar Rapids, IA
3 studies for Neuroblastoma are looking for participants at sites in and around Cedar Rapids (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
- University of Iowa Health Care. ( Site 1017), Iowa City · 25 mi away
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- New York City, NY12 studies
- Washington, DC11 studies
- Dallas, TX10 studies
- Cincinnati, OH9 studies
- St. Louis, MO9 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Aurora, CO9 studies
- Hartford, CT8 studies
- Birmingham, AL8 studies
- Harrisburg, PA8 studies
Other studies in Cedar Rapids
- Non-Small Cell Lung Cancer23 studies
- Breast Cancer17 studies
- Cancer (all types)17 studies
- Lung Cancer17 studies
- Multiple Myeloma16 studies
- Acute Myeloid Leukemia15 studies
- Colorectal Cancer14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Prostate Cancer12 studies
- Melanoma11 studies
- Metastatic Cancer9 studies
- Blood Cancers9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.